Novartis is considering bringing in PR agency supt to handle UK medical education and key opinionleader work for its transplant drug Myfortic.
PRWeek understands that agencies could soon be sounded out about a contract to handle med ed for the product, which only became available in the UK two months ago.
A UK spokeswoman for the Swissbased pharma giant would only say that “absolutely nothing” had yet been confirmed for the brand, adding that discussions remained “internal” to the Novartis brandg team.
She described meded plans for the brand as being at an “embryonic” stage.
Myfortic is an munosuppressant used to prevent the body rejecting a kidney transplant. By launching Myfortic, Novartis is set to take on the likes of Swiss rival Roche’s CellCept.
Myfortic completed the European Union’s Mutual Recognition Procedure in February. It received its first regulatory approval, from Switzerland, in October 2002. The US Food and Drug Administration has also given the thumbsup for g in the States.
Novartis’s UK agencies include Red Door Communications, Cohn & Wolfe and Ruder Finn.
